Objective:To describe the self-management(SM)behavior among persons with mild-to-moderate chronic obstructive pulmonary disease(COPD),and it examines the correlation between COPD knowledge,self-efficacy,perceived soci...Objective:To describe the self-management(SM)behavior among persons with mild-to-moderate chronic obstructive pulmonary disease(COPD),and it examines the correlation between COPD knowledge,self-efficacy,perceived social support,and SM behavior among persons with mild-to-moderate COPD in Wenzhou,China.Methods:A simple random sampling technique was used to recruit 121 persons with mild-to-moderate COPD who visited the respiratory outpatient department of the First Affiliated Hospital of Wenzhou Medical University in Wenzhou,China.Research instruments include a demographic data questionnaire,COPD SM scale,COPD knowledge questionnaire,6-item chronic disease self-efficacy scale,and perceived social suppor t scale.Descriptive statistics and Pearson's Correlation were used for data analysis.Results:The findings show that the mean score of COPD SM scale was 2.70(SD=0.45).The Pearson correlation analysis revealed that the COPD knowledge(r=0.47,P<0.001),self-efficacy(r=0.28,P=0.001),and perceived social support(r=0.48,P<0.001)were positively correlated to the COPD SM behavior among persons with mild-to-moderate COPD in Wenzhou,China.Conclusions:The findings indicate that disease knowledge,self-efficacy,and perceived social support were related to SM behavior in persons with mild-to-moderate COPD,which provides a theoretical basis for developing SM interventions for persons with mildto-moderate COPD and improving this population's SM behavior.展开更多
Background:The incidence of cognitive impairment(CI)is gradually increasing,which has attracted more attention from medical researchers worldwide.Definitive mechanisms of pathogenesis remain elusive,and there are few ...Background:The incidence of cognitive impairment(CI)is gradually increasing,which has attracted more attention from medical researchers worldwide.Definitive mechanisms of pathogenesis remain elusive,and there are few medications that have been proven effective for CI.The utilization of Chinese herbal medicine has shown positive therapeutic effects for a broad spectrum of diseases,including CI.Objective:The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules(GLJC,龟龄集胶囊)in treating mild-to-moderate CI with Shen(Kidney)and marrow deficiency syndrome.Methods:This is a randomized,double-blind,positive-controlled,multicenter clinical trial with a noninferiority design that included 348 participants randomly divided into an experimental arm and an active comparator arm.Individuals in the experimental arm(174 cases)took 0.6 g of GLJC once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day.Individuals in the active comparator arm(174 cases)took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day.The intervention period included two sessions over 24 weeks.The primary outcome be the effectiveness of GLJC on cognitive improvement after 24 weeks of treatment,which was defined as an increase in the Mini Mental State Examination(MMSE)and Montreal Cognitive Assessment(MoCA)Scale.The secondary outcomes were improvement in independence,daily living ability,and Chinese medicine(CM)syndrome,which were measured with the Alzheimer’s disease Rating Scale-Cognitive Project(ADAS-Cog),Clinical Dementia Rating(CDR)Total Score,Activities of Daily Living(ADL)Total Score and the Chinese Medicine Symptom Scale(CM-SS),respectively.Serum acetylcholine,acetylcholinesterase,bax and bcl-2 were monitored to explore the mechanism of GLJC on CI.In addition,safety measures,including vital signs,electrocardiography,laboratory indicators(full blood count,kidney and liver function tests,routine urine test and routine stool test)and adverse events,were also recorded.Discussion:The purpose of this trial is to evaluate the efficacy and safety of GLJC in patients with mild-to-moderate CI with kidney and marrow deficiency syndrome.If successful,the results would provide a viable treatment for patients with mild-to-moderate CI.展开更多
BACKGROUND Depression is recognized as a major public health problem with a substantial impact on individuals and society.Complementary therapies such as acupressure may be considered a safe and cost-effective treatme...BACKGROUND Depression is recognized as a major public health problem with a substantial impact on individuals and society.Complementary therapies such as acupressure may be considered a safe and cost-effective treatment for people with depression.An increasing body of research has been undertaken to assess the effectiveness of acupressure in various populations with depression,but the evidence thus far is inconclusive.AIM To examine the efficacy of acupressure on depression.METHODS A systematic literature search was performed on PubMed,PsycINFO,Scopus,Embase,MEDLINE,and China National Knowledge(CNKI).Randomized clinical trials(RCTs)or single-group trials in which acupressure was compared with control methods or baseline in people with depression were included.Data were synthesized using a random-effects or a fixed-effects model to analyze the impacts of acupressure treatment on depression and anxiety in people with depression.The primary outcome measures were set for depression symptoms.Subgroups were created,and meta-regression analyses were performed to explore which factors are relevant to the greater or lesser effects of treating symptoms.RESULTS A total of 14 RCTs(1439 participants)were identified.Analysis of the betweengroup showed that acupressure was effective in reducing depression[Standardized mean differences(SMDs)=-0.58,95%CI:-0.85 to-0.32,P<0.0001]and anxiety(SMD=-0.67,95%Cl:-0.99 to-0.36,P<0.0001)in participants with mildto-moderate primary and secondary depression.Subgroup analyses suggested that acupressure significantly reduced depressive symptoms compared with different controlled conditions and in participants with different ages,clinical conditions,and duration of intervention.Adverse events,including hypotension,dizziness,palpitation,and headache,were reported in one study.CONCLUSION The evidence of acupressure for mild-to-moderate depressive symptoms was significant.Importantly,the findings should be interpreted with caution due to study limitations.Future research with a well-designed mixed method is required to consolidate the conclusion and provide an in-depth understanding of potential mechanisms underlying the effects.展开更多
Chronic hypertension complicates 3%-5% of pregnancies and gestational hypertension occurs in 6% of pregnancies.Preeclampsia complicates 25% of the pregnancies with chronic hypertension,and approximately 15%-45% of the...Chronic hypertension complicates 3%-5% of pregnancies and gestational hypertension occurs in 6% of pregnancies.Preeclampsia complicates 25% of the pregnancies with chronic hypertension,and approximately 15%-45% of the patients with gestational hypertension will develop preeclampsia,a dangerous condition that harms the maternal and fetal safety.Antihypertensive medication is used to treat severe hypertension to prevent serious maternal and fetal complications,but there is no consensus on when and how to treat mild-to-moderate hypertension in pregnancy.This article reviews the usage,effect and safety of first,second and third line antihypertensive drugs for mild-to-moderate hypertension in pregnancy.展开更多
文摘Objective:To describe the self-management(SM)behavior among persons with mild-to-moderate chronic obstructive pulmonary disease(COPD),and it examines the correlation between COPD knowledge,self-efficacy,perceived social support,and SM behavior among persons with mild-to-moderate COPD in Wenzhou,China.Methods:A simple random sampling technique was used to recruit 121 persons with mild-to-moderate COPD who visited the respiratory outpatient department of the First Affiliated Hospital of Wenzhou Medical University in Wenzhou,China.Research instruments include a demographic data questionnaire,COPD SM scale,COPD knowledge questionnaire,6-item chronic disease self-efficacy scale,and perceived social suppor t scale.Descriptive statistics and Pearson's Correlation were used for data analysis.Results:The findings show that the mean score of COPD SM scale was 2.70(SD=0.45).The Pearson correlation analysis revealed that the COPD knowledge(r=0.47,P<0.001),self-efficacy(r=0.28,P=0.001),and perceived social support(r=0.48,P<0.001)were positively correlated to the COPD SM behavior among persons with mild-to-moderate COPD in Wenzhou,China.Conclusions:The findings indicate that disease knowledge,self-efficacy,and perceived social support were related to SM behavior in persons with mild-to-moderate COPD,which provides a theoretical basis for developing SM interventions for persons with mildto-moderate COPD and improving this population's SM behavior.
基金Supported by Beijing Municipal Science and Technology Project(Capital Characteristic Clinic Project,No.Z171100001017106)Beijing Municipal Science and Technology Project"Ten Disease and Ten Medicine"(No.Z171100001717016)。
文摘Background:The incidence of cognitive impairment(CI)is gradually increasing,which has attracted more attention from medical researchers worldwide.Definitive mechanisms of pathogenesis remain elusive,and there are few medications that have been proven effective for CI.The utilization of Chinese herbal medicine has shown positive therapeutic effects for a broad spectrum of diseases,including CI.Objective:The purpose of this study is to evaluate the safety and efficacy of Guilingji Capsules(GLJC,龟龄集胶囊)in treating mild-to-moderate CI with Shen(Kidney)and marrow deficiency syndrome.Methods:This is a randomized,double-blind,positive-controlled,multicenter clinical trial with a noninferiority design that included 348 participants randomly divided into an experimental arm and an active comparator arm.Individuals in the experimental arm(174 cases)took 0.6 g of GLJC once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day.Individuals in the active comparator arm(174 cases)took 0.6 g of GLJC mimetic once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day.The intervention period included two sessions over 24 weeks.The primary outcome be the effectiveness of GLJC on cognitive improvement after 24 weeks of treatment,which was defined as an increase in the Mini Mental State Examination(MMSE)and Montreal Cognitive Assessment(MoCA)Scale.The secondary outcomes were improvement in independence,daily living ability,and Chinese medicine(CM)syndrome,which were measured with the Alzheimer’s disease Rating Scale-Cognitive Project(ADAS-Cog),Clinical Dementia Rating(CDR)Total Score,Activities of Daily Living(ADL)Total Score and the Chinese Medicine Symptom Scale(CM-SS),respectively.Serum acetylcholine,acetylcholinesterase,bax and bcl-2 were monitored to explore the mechanism of GLJC on CI.In addition,safety measures,including vital signs,electrocardiography,laboratory indicators(full blood count,kidney and liver function tests,routine urine test and routine stool test)and adverse events,were also recorded.Discussion:The purpose of this trial is to evaluate the efficacy and safety of GLJC in patients with mild-to-moderate CI with kidney and marrow deficiency syndrome.If successful,the results would provide a viable treatment for patients with mild-to-moderate CI.
文摘BACKGROUND Depression is recognized as a major public health problem with a substantial impact on individuals and society.Complementary therapies such as acupressure may be considered a safe and cost-effective treatment for people with depression.An increasing body of research has been undertaken to assess the effectiveness of acupressure in various populations with depression,but the evidence thus far is inconclusive.AIM To examine the efficacy of acupressure on depression.METHODS A systematic literature search was performed on PubMed,PsycINFO,Scopus,Embase,MEDLINE,and China National Knowledge(CNKI).Randomized clinical trials(RCTs)or single-group trials in which acupressure was compared with control methods or baseline in people with depression were included.Data were synthesized using a random-effects or a fixed-effects model to analyze the impacts of acupressure treatment on depression and anxiety in people with depression.The primary outcome measures were set for depression symptoms.Subgroups were created,and meta-regression analyses were performed to explore which factors are relevant to the greater or lesser effects of treating symptoms.RESULTS A total of 14 RCTs(1439 participants)were identified.Analysis of the betweengroup showed that acupressure was effective in reducing depression[Standardized mean differences(SMDs)=-0.58,95%CI:-0.85 to-0.32,P<0.0001]and anxiety(SMD=-0.67,95%Cl:-0.99 to-0.36,P<0.0001)in participants with mildto-moderate primary and secondary depression.Subgroup analyses suggested that acupressure significantly reduced depressive symptoms compared with different controlled conditions and in participants with different ages,clinical conditions,and duration of intervention.Adverse events,including hypotension,dizziness,palpitation,and headache,were reported in one study.CONCLUSION The evidence of acupressure for mild-to-moderate depressive symptoms was significant.Importantly,the findings should be interpreted with caution due to study limitations.Future research with a well-designed mixed method is required to consolidate the conclusion and provide an in-depth understanding of potential mechanisms underlying the effects.
文摘Chronic hypertension complicates 3%-5% of pregnancies and gestational hypertension occurs in 6% of pregnancies.Preeclampsia complicates 25% of the pregnancies with chronic hypertension,and approximately 15%-45% of the patients with gestational hypertension will develop preeclampsia,a dangerous condition that harms the maternal and fetal safety.Antihypertensive medication is used to treat severe hypertension to prevent serious maternal and fetal complications,but there is no consensus on when and how to treat mild-to-moderate hypertension in pregnancy.This article reviews the usage,effect and safety of first,second and third line antihypertensive drugs for mild-to-moderate hypertension in pregnancy.
